New Insights on Cholangiocarcinoma

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2010 Dec 17

PMID 21160821

Citations 21

Authors

Manuela Gatto

Domenico Alvaro

Affiliations

Soon will be listed here.

Abstract

Cholangiocarcinoma (CCA) is a devastating cancer arising from the neoplastic transformation of the biliary epithelium. It is characterized by a progressive increase in incidence and prevalence. The only curative therapy is radical surgery or liver transplantation but, unfortunately, the majority of patients present with advanced stage disease, which is not amenable to surgical therapies. Recently, proposed serum and bile biomarkers could help in the screening and surveillance of categories at risk and in diagnosing CCA at an early stage. The molecular mechanisms triggering neoplastic transformation and growth of biliary epithelium are still undefined, but significant progress has been achieved in the last few years. This review deals with the most recent advances on epidemiology, biology, and clinical management of CCA.

Citing Articles

Clinical and Imaging Features of a Focal Intrahepatic Biliary Stricture Visualized Only as Duct Dilatation.

Kim B, Kim M, Kim M, Yi J, Paek J, Lee H J Korean Soc Radiol. 2024; 85(6):1157-1168.

PMID: 39660320 PMC: 11625844. DOI: 10.3348/jksr.2023.0096.

Effects of 2-dodecyl-6-methoxycyclohexa-2,5-diene-1,4-dione on autophagy and the PI3K/AKT/mTOR signaling pathway in human cholangiocarcinoma QBC939 cells.

He Y, Li Y, Liang T, Mo S, Liao Y, Chen Z J Gastrointest Oncol. 2022; 13(3):1423-1432.

PMID: 35837172 PMC: 9274070. DOI: 10.21037/jgo-22-298.

A novel mouse model of orthotopic extrahepatic cholangiocarcinoma confirmed with molecular imaging.

Song X, Shao Z, Han M, Liang H Transl Cancer Res. 2022; 8(2):583-591.

PMID: 35116791 PMC: 8798838. DOI: 10.21037/tcr.2019.03.19.

Oxaliplatin reverses the GLP-1R-mediated promotion of intrahepatic cholangiocarcinoma by altering FoxO1 signaling.

Chen B, Zhou W, Zhao W, Yuan P, Tang C, Wang G Oncol Lett. 2019; 18(2):1989-1998.

PMID: 31423269 PMC: 6607039. DOI: 10.3892/ol.2019.10497.

Modern work-up and extended resection in perihilar cholangiocarcinoma: the AMC experience.

Rassam F, Roos E, van Lienden K, van Hooft J, Klumpen H, van Tienhoven G Langenbecks Arch Surg. 2018; 403(3):289-307.

PMID: 29350267 PMC: 5986829. DOI: 10.1007/s00423-018-1649-2.

References

Akdogan M, Sasmaz N, Kayhan B, Biyikoglu I, Disibeyaz S, Sahin B . Extraordinarily elevated CA19-9 in benign conditions: a case report and review of the literature. Tumori. 2002; 87(5):337-9. DOI: 10.1177/030089160108700513. View

Anderson C, Kim R . Adjuvant therapy for resected extrahepatic cholangiocarcinoma: a review of the literature and future directions. Cancer Treat Rev. 2009; 35(4):322-7. DOI: 10.1016/j.ctrv.2008.11.009. View

Lee J, Kim T, Lee M, Ahn M, Kim H, Lim H . Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemother Pharmacol. 2007; 61(1):47-52. DOI: 10.1007/s00280-007-0444-5. View

Ishiguro S, Inoue M, Kurahashi N, Iwasaki M, Sasazuki S, Tsugane S . Risk factors of biliary tract cancer in a large-scale population-based cohort study in Japan (JPHC study); with special focus on cholelithiasis, body mass index, and their effect modification. Cancer Causes Control. 2007; 19(1):33-41. DOI: 10.1007/s10552-007-9067-8. View

Endo K, Yoon B, Pairojkul C, Demetris A, Sirica A . ERBB-2 overexpression and cyclooxygenase-2 up-regulation in human cholangiocarcinoma and risk conditions. Hepatology. 2002; 36(2):439-50. DOI: 10.1053/jhep.2002.34435. View

Olnes M, Erlich R . A review and update on cholangiocarcinoma. Oncology. 2004; 66(3):167-79. DOI: 10.1159/000077991. View

Kang Y, Kim W, Lee H, Lee H, Kim Y . Mutation of p53 and K-ras, and loss of heterozygosity of APC in intrahepatic cholangiocarcinoma. Lab Invest. 1999; 79(4):477-83. View

Casavilla F, Marsh J, Iwatsuki S, Todo S, Lee R, Madariaga J . Hepatic resection and transplantation for peripheral cholangiocarcinoma. J Am Coll Surg. 1997; 185(5):429-36. PMC: 2958518. DOI: 10.1016/s1072-7515(97)00088-4. View

Kiesslich T, Wolkersdorfer G, Neureiter D, Salmhofer H, Berr F . Photodynamic therapy for non-resectable perihilar cholangiocarcinoma. Photochem Photobiol Sci. 2009; 8(1):23-30. DOI: 10.1039/b813183j. View

10.

Welzel T, Graubard B, El-Serag H, Shaib Y, Hsing A, Davila J . Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study. Clin Gastroenterol Hepatol. 2007; 5(10):1221-8. PMC: 2083573. DOI: 10.1016/j.cgh.2007.05.020. View

11.

Pinlaor S, Sripa B, Ma N, Hiraku Y, Yongvanit P, Wongkham S . Nitrative and oxidative DNA damage in intrahepatic cholangiocarcinoma patients in relation to tumor invasion. World J Gastroenterol. 2005; 11(30):4644-9. PMC: 4615404. DOI: 10.3748/wjg.v11.i30.4644. View

12.

Blechacz B, Gores G . Cholangiocarcinoma. Clin Liver Dis. 2008; 12(1):131-50, ix. DOI: 10.1016/j.cld.2007.11.003. View

13.

Voyles C, Smadja C, SHANDS W, Blumgart L . Carcinoma in choledochal cysts. Age-related incidence. Arch Surg. 1983; 118(8):986-8. DOI: 10.1001/archsurg.1983.01390080088022. View

14.

Lempinen M, Isoniemi H, Makisalo H, Nordin A, Halme L, Arola J . Enhanced detection of cholangiocarcinoma with serum trypsinogen-2 in patients with severe bile duct strictures. J Hepatol. 2007; 47(5):677-83. DOI: 10.1016/j.jhep.2007.05.017. View

15.

Nakeeb A, Pitt H, Sohn T, Coleman J, Abrams R, Piantadosi S . Cholangiocarcinoma. A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg. 1996; 224(4):463-73; discussion 473-5. PMC: 1235406. DOI: 10.1097/00000658-199610000-00005. View

16.

Fava G, Marzioni M, Benedetti A, Glaser S, DeMorrow S, Francis H . Molecular pathology of biliary tract cancers. Cancer Lett. 2006; 250(2):155-67. DOI: 10.1016/j.canlet.2006.09.011. View

17.

Nehls O, Oettle H, Hartmann J, Hofheinz R, Hass H, Horger M . Capecitabine plus oxaliplatin as first-line treatment in patients with advanced biliary system adenocarcinoma: a prospective multicentre phase II trial. Br J Cancer. 2008; 98(2):309-15. PMC: 2361467. DOI: 10.1038/sj.bjc.6604178. View

18.

Itatsu K, Sasaki M, Yamaguchi J, Ohira S, Ishikawa A, Ikeda H . Cyclooxygenase-2 is involved in the up-regulation of matrix metalloproteinase-9 in cholangiocarcinoma induced by tumor necrosis factor-alpha. Am J Pathol. 2009; 174(3):829-41. PMC: 2665744. DOI: 10.2353/ajpath.2009.080012. View

19.

Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W, Nakanuma Y . Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology. 1999; 35(3):230-40. DOI: 10.1046/j.1365-2559.1999.00705.x. View

20.

Meyerhardt J, Zhu A, Stuart K, Ryan D, Blaszkowsky L, Lehman N . Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer. Dig Dis Sci. 2007; 53(2):564-70. DOI: 10.1007/s10620-007-9885-2. View